Navigation Links
In vivo Study Results Demonstrating Potential of Alfacell's,Onconase for Treatment of Non-Small Cell Lung Cancer Published in,Anticancer Research

BLOOMFIELD, N.J., March 26, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that in vivo study results demonstrating the potential of ONCONASE (ranpirnase) for the treatment of non-small cell lung cancer (NSCLC) were recently published in Anticancer Research (2007; 27: 299- 308).

Based on the work of Intae Lee, Ph.D., at the University of Pennsylvania, a paper entitled "Antitumor Efficacy of the Cytotoxic RNase, Ranpirnase, on A549 Human Lung Cancer Xenografts of Nude Mice" shows that:

    * ONCONASE significantly inhibited tumor growth of A549 NSCLC cells both

      in vitro and in vivo; apoptosis was significantly induced by ONCONASE in

      a dose-dependent manner


    * Multiple small doses of ONCONASE were more effective than one large

      single dose of ONCONASE for the inhibition of tumor growth in animal

      studies


    * ONCONASE in combination with cisplatin significantly reduced tumor

      growth of A549 cells; in large tumors, including those unsuccessfully

      treated with cisplatin previously, ONCONASE demonstrated inhibition of

      tumor growth

"ONCONASE has important potential clinical uses for the treatment of NSCLC," said Dr. Lee. "We are pleased that the results of our studies have helped to guide the clinical development of ONCONASE for NSCLC."

Kuslima Shogen, Alfacell's chairman and chief executive officer, said, "The publication of this paper in an important peer-reviewed journal is further recognition of the potential of ONCONASE. This data is evidence that ONCONASE has the potential to overcome resistance to, and enhance the performance of, cisplatin. We expect to continue advancing ONCONASE through the development process as we work to build a broad franchise in different therapeutic areas and via multiple treatment modalities."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic based on Alf
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/16/2014)... , Oct. 16, 2014 The ... guidance on the application of single-use, or ... pharmaceutical and biopharmaceutical products with the publication ... Application of Single-Use Systems in Pharmaceutical ... described as single-use systems (SUS) or single-use ...
(Date:10/16/2014)... , Oct. 16, 2014 Curtis & ... under 3 weeks away from hosting their co-located ... Oral Drug Formulation Innovations Summit taking place ... San Diego, CA. November,s events ... organizations in streamlining the bioequivalence testing process, as well ...
(Date:10/16/2014)... PHILADELPHIA , Oct. 16, 2014 Ninety ... (ALL) who had relapsed multiple times or failed to ... an investigational personalized cellular therapy, CTL019, developed at the ... The results published today in The ... new data, which builds on preliminary findings presented at ...
Breaking Medicine Technology:PDA Offers Help in Applying Single-Use Systems to Bio/Pharma Operations 2Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6
... Health Corp. (Nasdaq: WBMD ) today announced the ... amount of 2.50% Convertible Notes due 2018 (including $50 million ... full of the initial purchaser,s over-allotment option).  The notes were ... under the Securities Act of 1933.   The ...
... NEW YORK, Jan. 11, 2011 Reportlinker.com ... is available in its catalogue: ... Price cuts set to negatively impact both ... http://www.reportlinker.com/p0360216/Spain-Pharmaceutical-Market-Overview – Price-cuts-set-to-negatively-impact-both-branded-and-generics-companies.html ...
Cached Medicine Technology:WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2Reportlinker Adds Spain Pharmaceutical Market Overview - Price cuts set to negatively impact both branded and generics companies 2
(Date:10/18/2014)... The famous review site Top10BestSEOHosting.com has recently compared many ... suppliers carefully, today it announces that HostMonster, GreenGeeks and ... first half of 2014. , HostMonster is an ... package helps business companies and individuals get high-powered service ... rated hosting provider, it insists on offering outstanding customer ...
(Date:10/18/2014)... (PRWEB) October 19, 2014 ... announced that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), JustHost ... suppliers in 2014. , “There are ... world, but good suppliers are not too ... and FatCow are the most outstanding suppliers ...
(Date:10/18/2014)... Operators in the Carpet ... carpet cleaning services, such as steam cleaning, dry-cleaning ... every one to two years. According to IBISWorld ... plummeted during the peak of the global financial ... carpet cleaning.” The upward trend in household discretionary ...
(Date:10/18/2014)... TX (PRWEB) October 18, 2014 ... Chinese Chondroitin sulfate Industry, 2009-2019 is a ... Global and Chinese Chondroitin sulfate industry. The ... Chondroitin sulfate including its classification, application and ... and China’s top manufacturers of Chondroitin sulfate ...
(Date:10/18/2014)... determined dieters can fail if they don,t have a ... Their new study included 240 obese people. All of ... factors that increase the risk of heart disease, stroke ... to make lifestyle changes, including improved eating, the study ... clinical trial comparing two dietary interventions: the American ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: HostMonster, GreenGeeks And FatCow Are The Best PHP Hosting Suppliers In The First Half Of 2014 2Health News:Top10BestSEOHosting.com: Best Reseller Hosting Companies Announced 2Health News:Carpet Cleaning Services in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Carpet Cleaning Services in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 2Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 3Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 4Health News:Dieters May Be Thwarted by Absence of Healthy Foods 2
... America, Inc. (SAI),today announced the 1,000th activation ... Hagerstown Medical Laboratory, Maryland.,SNCS is a remote ... tracks instrument performance data from Sysmex analyzers ... SNCS enables proactive response to potential,instrument problems, ...
... Medications May Disappear or be Hindered For ... California,s Most Vulnerable Citizens, SACRAMENTO, Calif., ... against the California Department of,Health Care Services and its director ... pharmacies from going into effect on July 1,2008. The action ...
... Raising Awareness ... & Education, NEW YORK, June 10 MGM ... branding initiative, PiNKiTUDE, which,will encompass a wide range of ... earmarked for the global breast cancer organization,Susan G. Komen ...
... June 5, 2008 Over 1.3 million Americans ... of the joints. RA is a disabling condition, and ... pain and loss of function in affected areas. A ... Journal of Periodontology , the official publication of ...
... regimen of the immune-suppressing drug cyclophosphamide seems to slow ... small group of patients studied and may even restore ... report. The findings in nine people, most of whom ... treat a disease that tends to progress relentlessly. , ...
... Promote Health and ... Wellness, ... meeting consumers, health and wellness needs, the Kellogg,Company joined the Department of ... companies,promoting eating and physical fitness for families that is consistent with,MyPyramid. The ...
Cached Medicine News:Health News:Sysmex America to Enable Prolonged Hematology Instrument Uptime for Hagerstown Medical Laboratory With 1,000th SNCS Activation 2Health News:Sysmex America to Enable Prolonged Hematology Instrument Uptime for Hagerstown Medical Laboratory With 1,000th SNCS Activation 3Health News:Eight California Pharmacies File Lawsuit Against the California Department of Health Care Services to Stop the 10 Percent Medi-Cal Provider Cuts to Pharmacies 2Health News:PiNKiTUDE, New Cause Marketing Initiative Inspired by MGM's Pink Panther, Benefits Susan G. Komen for the Cure(R) 2Health News:PiNKiTUDE, New Cause Marketing Initiative Inspired by MGM's Pink Panther, Benefits Susan G. Komen for the Cure(R) 3Health News:PiNKiTUDE, New Cause Marketing Initiative Inspired by MGM's Pink Panther, Benefits Susan G. Komen for the Cure(R) 4Health News:Researchers uncover higher prevalence of periodontal disease in rheumatoid arthritis patients 2Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 2Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 3Health News:Kellogg and MyPyramid - Helping Families Live Well Today and Every Day 2Health News:Kellogg and MyPyramid - Helping Families Live Well Today and Every Day 3Health News:Kellogg and MyPyramid - Helping Families Live Well Today and Every Day 4
... physicians looking for a traditional ... communications with electronic storage features, ... best of both worlds. It ... features of the Atria 3000 ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: